A study on olfactory mucosa-derived stem cells for ischemic stroke is registered in Hainan

On November 4, 2026, China announced that a study on autologous olfactory mucosa-derived mesenchymal stem cells for ischemic stroke was registered in Hainan. Initiated by Hainan Susheng Biotechnology Co., Ltd., the project lists Haikou People's Hospital as its clinical research institution. Olfactory mucosa-derived cells provide a distinct source for investigating immunomodulation and neural repair. A 2025 study of hypoxia-preconditioned cells reported reduced microglial ferroptosis and neuroinflammation and improved neurological outcomes in experimental stroke models. These findings provide a preclinical rationale; the registered product's preparation and its effects in humans need to be clinically evaluated. For Hainan, the project links local scientific work with collaboration between a biotechnology enterprise and a hospital. Its contribution will depend on appropriate patient selection, credible study design, meaningful functional outcomes, reproducible cell manufacture, and long-term safety monitoring. Transparent reporting can make this experience informative for future stroke research and the development of regulated regenerative medicine.

Authors

Publication Details

Journal
BioScience Trends
Published
2026-11-18
DOI
https://doi.org/10.5582/bst.2026.01294
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A study on olfactory mucosa-derived stem cells for ischemic stroke is registered in Hainan

Ya-nan Ma, Ying Xia
BioScience Trends
Mesenchymal stem cell research
article

A study on olfactory mucosa-derived stem cells for ischemic stroke is registered in Hainan

Ya-nan Ma, Ying Xia
article en

Abstract

On November 4, 2026, China announced that a study on autologous olfactory mucosa-derived mesenchymal stem cells for ischemic stroke was registered in Hainan. Initiated by Hainan Susheng Biotechnology Co., Ltd., the project lists Haikou People's Hospital as its clinical research institution. Olfactory mucosa-derived cells provide a distinct source for investigating immunomodulation and neural repair. A 2025 study of hypoxia-preconditioned cells reported reduced microglial ferroptosis and neuroinflammation and improved neurological outcomes in experimental stroke models. These findings provide a preclinical rationale; the registered product's preparation and its effects in humans need to be clinically evaluated. For Hainan, the project links local scientific work with collaboration between a biotechnology enterprise and a hospital. Its contribution will depend on appropriate patient selection, credible study design, meaningful functional outcomes, reproducible cell manufacture, and long-term safety monitoring. Transparent reporting can make this experience informative for future stroke research and the development of regulated regenerative medicine.

BioScience Trends
NIH Clinical Center
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon